Intellia Therapeutics Inc (NTLA)

Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today

Zacks Investment Research

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates

GlobeNewswire Inc.

Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024

GlobeNewswire Inc.

Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?

Zacks Investment Research

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Zacks Investment Research

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update

Seeking Alpha

2 Stocks Down 30% to Buy Right Now

The Motley Fool

Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.

The Motley Fool

Bull Market and Beyond: 3 Stocks Just Waiting to Soar

The Motley Fool

Better Cathie Wood Stock: Moderna vs. Intellia

The Motley Fool

Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study

Zacks Investment Research

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

GlobeNewswire Inc.

Is Intellia Therapeutics Stock a Buy Now?

The Motley Fool

Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst

The Motley Fool

A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now

The Motley Fool

Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors

Zacks Investment Research

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The Motley Fool

Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average

Zacks Investment Research

Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed

Benzinga

Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update

Zacks Investment Research

Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High?

Zacks Investment Research

Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More

Zacks Investment Research

Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought

The Motley Fool

Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?

Zacks Investment Research

Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?

The Motley Fool

C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?

Zacks Investment Research

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks Investment Research

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

Zacks Investment Research

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

GlobeNewswire Inc.

5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

Zacks Investment Research

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

Zacks Investment Research

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates

GlobeNewswire Inc.

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

Zacks Investment Research

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The Motley Fool

Not Shy Of Buying The Dip, Cathie Wood's Ark Mops Up Over $11M Worth Of Shares In Tesla — Sells Nvidia Stock

Benzinga

A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist

The Motley Fool

Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?

Zacks Investment Research

Cathie Wood's Ark Invest Snatches Up $4.7M More In Tesla Shares, Invests Equally In This Rocket Company

Benzinga

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

GlobeNewswire Inc.

History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.

The Motley Fool

Down -19.06% in 4 Weeks, Here's Why Intellia Therapeutics, Inc. (NTLA) Looks Ripe for a Turnaround

Zacks Investment Research

2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street

The Motley Fool

Is It Too Late to Buy Intellia Therapeutics Stock?

The Motley Fool

Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics

The Motley Fool

Is it a Good Idea to Invest in Intellia (NTLA) Stock Now?

Zacks Investment Research

Dow Jones Extends Historic Streak: Are More All-Time Highs in the Cards?

Investing.com

The Top Healthcare Stocks to Buy With $100

The Motley Fool

Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now?

Zacks Investment Research

Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics

The Motley Fool